Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRH
CRH
|
+$978M |
| 2 |
Microsoft
MSFT
|
+$812M |
| 3 |
Bank of America
BAC
|
+$602M |
| 4 |
Apple
AAPL
|
+$518M |
| 5 |
NVIDIA
NVDA
|
+$412M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$1.32B |
| 2 |
State Street Materials Select Sector SPDR ETF
XLB
|
+$1.12B |
| 3 |
State Street Communication Services Select Sector SPDR ETF
XLC
|
+$958M |
| 4 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$940M |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$816M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.45% |
| 2 | Financials | 11.83% |
| 3 | Healthcare | 11.27% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Communication Services | 7.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3901
Angi Inc
ANGI
$229M
| $29.4K | ﹤0.01% |
1,483
+62
| +4% | +$1.77K |
|
3902
Celcuity
CELC
$4.21B
| $29.2K | ﹤0.01% |
3,191
-260
| -8% | -$2.56K |
|
3903
GrowGeneration
GRWG
$86.5M
| $29.1K | ﹤0.01% |
9,971
-1,727
| -15% | -$5.66K |
|
3904
Gyre Therapeutics
GYRE
$641M
| $29K | ﹤0.01% |
4,014
| – | – |
|
3905
Kinetik
KNTK
$3.72B
| $29K | ﹤0.01% |
859
-6,910
| -89% | -$243K |
|
3906
Trevi Therapeutics
TRVI
$2.59B
| $29K | ﹤0.01% |
13,285
-767
| -5% | -$1.73K |
|
|
FSFG
3907
DELISTED
First Savings Financial Group
FSFG
| $28.9K | ﹤0.01% |
1,964
| – | – |
|
3908
ESS Tech
GWH
$22M
| $28.9K | ﹤0.01% |
1,025
-241
| -19% | -$5.86K |
|
3909
Zevra Therapeutics
ZVRA
$562M
| $28.8K | ﹤0.01% |
5,965
-971
| -14% | -$4.85K |
|
|
DFTX
3910
Definium Therapeutics
DFTX
$5.78B
| $28.6K | ﹤0.01% |
9,147
| – | – |
|
|
NSTG
3911
DELISTED
NanoString Technologies, Inc.
NSTG
| $28.6K | ﹤0.01% |
16,643
-1,203
| -7% | -$3.66K |
|
3912
Barclays
BCS
$92.7B
| $28.6K | ﹤0.01% |
3,665
| – | – |
|
|
SMLR
3913
DELISTED
Semler Scientific
SMLR
| $28.5K | ﹤0.01% |
1,124
+125
| +13% | +$3.25K |
|
|
HEAL
3914
Global X Funds Global X HealthTech ETF
HEAL
$28.5M
| $28.4K | ﹤0.01% |
1,031
| – | – |
|
3915
Lineage Cell Therapeutics
LCTX
$269M
| $28.3K | ﹤0.01% |
23,996
-1,909
| -7% | -$2.6K |
|
3916
Global Partners
GLP
$1.68B
| $28.3K | ﹤0.01% |
801
-363
| -31% | -$11.6K |
|
|
NEWP
3917
New Pacific Metals
NEWP
$859M
| $28K | ﹤0.01% |
15,821
+195
| +1% | +$457 |
|
3918
Weyco Group
WEYS
$372M
| $27.8K | ﹤0.01% |
1,096
-113
| -9% | -$3K |
|
3919
Vertical Aerospace
EVTL
$158M
| $27.7K | ﹤0.01% |
2,351
| – | – |
|
3920
PCB Bancorp
PCB
$392M
| $27.7K | ﹤0.01% |
1,790
-846
| -32% | -$13.5K |
|
3921
Cue Biopharma
CUE
$113M
| $27.6K | ﹤0.01% |
400
-32
| -7% | -$3.12K |
|
3922
Actinium Pharmaceuticals
ATNM
$26.3M
| $27.5K | ﹤0.01% |
4,652
-533
| -10% | -$3.55K |
|
3923
Orchestra BioMed
OBIO
$238M
| $27.5K | ﹤0.01% |
3,153
+28
| +0.9% | +$188 |
|
3924
Quad
QUAD
$536M
| $27.5K | ﹤0.01% |
5,464
-202,073
| -97% | -$1.06M |
|
3925
Virginia National Bankshares
VABK
$248M
| $27.4K | ﹤0.01% |
902
-42
| -4% | -$1.43K |
|
Similar funds
Barclays's Q3 2023 Portfolio in Review
As of Q3 2023, Barclays held 4,832 positions worth $161B, up 1.7% from $158B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Barclays deployed $8.05B of net new capital in Q3 2023, opening 336 new positions and adding to 1,838 existing holdings. Its largest new stake was CRH: 17,203,754 shares worth $942M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 28% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Invesco QQQ Trust, an estimated $1.32B trimmed.
- Barclays's largest Q3 2023 buy was CRH: 17,203,754 shares worth $942M.
- Barclays added most to Microsoft in Q3 2023, an estimated $812M increase.
- Barclays's biggest Q3 2023 reduction was Invesco QQQ Trust, cutting an estimated $1.32B.
- Barclays fully exited Aerojet Rocketdyne Holdings in Q3 2023, selling an estimated $154M.
- Barclays's ten largest holdings make up 24% of its $161B portfolio in Q3 2023.
- Barclays opened 336 new positions and closed 249 in Q3 2023.
- Barclays's portfolio value rose 1.7% quarter-over-quarter to $161B.
Based on Barclays's 13F filing for Q3 2023, filed 7 Nov 2023.